The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kmxniC
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Mingan Yu, Duqiang Liu, ...
-
Abstract Endurance exercise generates CO 2 via aerobic metabolism; however, its role remains unclear. Exogenous CO 2 by transcutaneous d...
-
The NO(X(2)Π) + N((4)S) reaction which occurs entirely in the triplet manifold of N2O is investigated using quasiclassical trajectories and ...
-
One third of adult patients with orthognathic surgery of a prognathic or retrognathic mandible show relapse. The sagittal split osteotomy of...
-
Medicine by Alexandros G. Sfakianakis BioMed Research International BioMed Research InternationalTanshinone IIA Alleviates CCL2-Induced Le...
-
We present a small-scale fading analysis of the vehicular-to-vehicular (V2V) propagation channel at 5.9 GHz when both the transmitter (Tx) a...
-
The nanoanalytical high resolution TEM/STEM investigation of the intergranular grain boundary phase of anisotropic sintered and rapidly quen...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nNKGGx via IFTTT
-
People who smoke may metabolise caffeine differently to non-smokers, leaving them needing to drink more to get the same hit from their coff...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου